Article information
Full text is only aviable in PDF
Bibliografía
[1.]
H. Morrow-Brown, G. Storey, W.H.S. George.
Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma.
Br Med J, 1 (1972), pp. 585-590
[3.]
A.M. Bentley, G. Menz, C. Storz, et al.
Identification of T-lymphocytes, macrophages and activated eosinophils in the bronchial mucosa in intrinsic asthsma: relationship to symptoms and bronchial responsiveness.
Am Rev Respir Dis, 146 (1992), pp. 500-506
[4.]
J. Bousquet, P. Chanez, J.Y. Lacoste, et al.
Eosinophillic inflammation in asthma.
N Engl J Med, 323 (1990), pp. 1.033-1.039
[5.]
J. Kelley.
Cytokines of the lung.
Am Rev Respir Dis, 141 (1990), pp. 765-768
[6.]
A. Frew.
Asking the right questions in asthma.
Quaeritur: Imflamation Focus Y. Eur Respir Review, 4 (1994), pp. 24
[7.]
A.J. Knox, A.E. Tattersfield.
Airway smooth muscle relaxation.
Thorax, 50 (1995), pp. 894-901
[8.]
A. Ullman, N. Svedmyr.
Salmeterol, a new long-acting inhaled ß, adrenoceptor agonist: a comparison with salbutamol in asthmatic patients.
Thorax, 43 (1988), pp. 674-678
[9.]
P. Arvidsson, S. Larsson, C.G. Löfdhal, et al.
Formoterol: a new long acting bronchodilator for inhalation.
Eur Respir J, 2 (1989), pp. 325-330
[10.]
D. Cheung, M.C. Timmers, A. Zwinderman, E. Bel, et al.
The prolonged effects of salmeterol on airway hyperresponsiveness in asthma.
N Engl J Med, 327 (1992), pp. 1.198-1.203
[11.]
J.B.D. Palmer, F.M.C. Cuss, P.J. Barnes.
VIP and PHM and their role in nonadrenergic inhibitory responses in isolated human airways.
J Appl Physiol, 61 (1986), pp. L322-1.328
[12.]
M. Okayama, H. Sasaki, T. Takishima.
Bronchodilator effect of sublingual isosorbide dinitrate in asthma.
Eur J Clin Pharmacol, 26 (1984), pp. 151-155
[13.]
L. Hirschleiter, Y. Arora.
Nitrates in the treatment of bronchial asthma.
Dis Chest, 39 (1961), pp. 275-283
[14.]
K.F. Rabe, H. Tenor, G. Dent, et al.
Phosphodiesterase isoenzymes modulating inherent tone in human airways: identification and characterization.
Am J Physiol, 264 (1993), pp. 458-464
[15.]
T. Torphy, B. Undent.
Phosphodiesterase inhibitors: new oportunities for the treatment of asthma.
Thorax, 46 (1991), pp. 512-523
[16.]
K.F. Rabe, H. Magnussen, G. Dent.
Theophylline and selective PDE inhibitors as broncodilators and smooth muscle relaxants.
Eur Respir J, (1995), pp. 637-642
[17.]
E. Israel, P.N. Mathur, D. Tashkin, et al.
LY 186655 prevents bronchospasm in asthma of moderate severity [resumen].
Chest, 94 (1988), pp. 71
[18.]
R.M. Rudd, A.R. Geliert, P.R. Studdy, et al.
Inhibition of exercise-induced asthma by an orally absorbed mast stabiliser (M & B 22.948).
Br J Dis Chest, 77 (1983), pp. 78-86
[20.]
M. Perpiñá, C. Pellicer, V. Marco.
Nifedipine decreases sensitivity and reactivity to methacholine in mild asthmatics.
Respiration, 51 (1987), pp. 49-57
[21.]
J.L. Black, C. Armour, A. Johnson, et al.
The action of a potassium chanel activator. BRL 38227 (lemakalim) on human airway smooth muscle.
Am Rev Respir Dis, 142 (1990), pp. 1.384-1.389
[22.]
A.J. Williams, T.H. Lee, G.M. Cochrane, et al.
Attenuation of nocturnal asthma by cromakalim.
Lancet, 336 (1990), pp. 334-336
[23.]
A. De Diego, J. Cortijo, V. Villagrasa, et al.
H-7, a proteinkinase inhibitor. inhibits spontaneous tone and spasmogenic responses in normal and sensitized guinea-pig trachea.
Gen Pharmacol, 26 (1995), pp. 1.747-1.755
[24.]
M.F. Tosi, J.M. Stark, C.W. Smith, et al.
Induction of ICAM-1 expression on human airway epithelial cells by imflamatory cytokynes: effects of neutrophil-epithelial cell adhesion.
Am J Respir Cell Mol Biol, 7 (1992), pp. 214-221
[25.]
C.D. Wegner, L. Gundel, P. Reilly, et al.
Intracellular adhesion molecule 1 (ICAM-1) in the pathogenesis of asthma.
Science, 247 (1990), pp. 456-459
[26.]
D.S. Robinson, Q. Hamid, S. Ying, et al.
Predominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthma.
N Engl J Med, 326 (1992), pp. 298-304
[27.]
D.I. Bernstein, I.L. Bernstein, S.S. Bodenheimer, et al.
An open study of auranofin in the treatment of steoriddependent asthma.
J Allergy Clin Immunol, 81 (1988), pp. 6-16
[28.]
S.H. Lock, N.C. Barnes, A.B. Kay, A. Cyclosporin.
(CsA) as a corticosteroid sparing agent in corticosteroid dependent asthma.
Eur Respir J, 7 (1994), pp. 282
[29.]
M.F. Mullarkey, J.K. Lammert, B.A. Blummenstein.
Long-term methotrexate in corticosteroid-dependent asthma.
Ann Intern Medicine, 112 (1990), pp. 577-581
[30.]
M.J. Coffey, G. Sanders, Eschenbacher, et al.
The role of methotrexate in the management of steroid-dependent asthma.
Chest, 105 (1994), pp. 649-650
[31.]
B.L. Charous.
Open study of hidroxychloroquine in the treatment of sever symptomatic or corticosteroid-dependent asthma.
Ann Allergy, 65 (1990), pp. 53-58
[32.]
Y.A. Schwarz, S. Kivity, E. Feiermann, et al.
A clinical and immunological study of colchicine in asthma.
J Allergy Clin Immunol, 85 (1990), pp. 578-582
[33.]
B.D. Mazer, P.C. Giclas, E.W. Gelfand.
Immunomodulatory effects of intravenous immunoglobulin in severe steroid-dependent asthma.
Clin Immunol Immunopathol, 53 (1989), pp. 156-163
[34.]
A.J.M. Van Oosterhoot, A. Rudolf, C. Ladenius, et al.
Effect of antiIL-5 and IL-5 in airway hyperreactivity and eosinophils in guineapig.
Am Rev Respir Dis, 147 (1993), pp. 548-552
[35.]
R. Wood-Baker, S.T. Holgate.
The comparative actions and adverse effect profile of single dosis of H1-receptor antihistamines in the airways and skin of subjects with asthma.
J Allergy Clin Immunol, 91 (1993), pp. 1.005-1.014
[37.]
S.K. Ghosh, P. Rafferty, C. De Vos, et al.
Effect of cetirizine, a potent H1 antagonist, on platelet activating factor induced bronchoconstriction in asthma.
Clin Exp Allergy, 23 (1993), pp. 524-527
[38.]
M.C. Kopferschimitt-Kubler, A. Couchot, G. Pauli.
Evaluation of the effect of oral cetirizine on antigen-induced immediate asthmatic response.
Ann Allergy, 65 (1990), pp. 501-503
[39.]
J.A. Grant, M.M. Glowsky, E.O. Meltzer, et al.
Safety and efficacy of cetirizine in the prophylactic management of patients with seasonal allergic rhinithis and asthma.
J Allergy Clin Immunol, 91 (1993), pp. 197
[40.]
B. Samuelsson.
Leukotrienes: mediators of immediate hypertensisitivity reactions and inflammation.
Science, 220 (1983), pp. 568-575
[41.]
R.A. Lewis, K.F. Austen.
The biologically active leukotrienes.
J Clin Invest, 73 (1984), pp. 889-897
[42.]
N. Chanarin, S.L. Johnston.
Leukotrienes as a target in asthma therapy.
Drugs, 47 (1994), pp. 12-24
[43.]
C.M. Smith, P.E. Christie, R.J. Hawksworth, et al.
Urinary leukotriene E4 levels after allergen and exercise challengue in bronchial asthma.
Am Rev Respir Dis, 144 (1991), pp. 1.411-1.413
[44.]
S.E. Dahlen, P. Hedqvist, S. Hammarström, et al.
Leukotrienes are potent constrictors of human bronchi.
Nature, 288 (1980), pp. 484-486
[45.]
E. Alderoth, M.M. Morris, F.E. Hargreave, et al.
Airway responsiveness to LTC4 and D4 and to methacholine in patients with asthma and normal controls.
N Engl J Med, 315 (1986), pp. 480-484
[46.]
A.P. Ampson, R.U. Thomas, J.F. Costello, et al.
Enhanced leukotriene synthesis in leukocytes of atopic and asthmatic subjects.
Br J Pharmacol, 33 (1992), pp. 423-430
[47.]
A.J. Wardlaw, H. Hay, O. Cronwell, et al.
Leukotrienes. LTC4 and LTB4 in bronchoalveolar lavage in bronchila asthma and other respiratory diseases.
J Allergy Clin Immunol, 84 (1989), pp. 19-26
[48.]
J.P. Finnerty, R. Wood-Baker, H. Thomson, et al.
Role of cysteinylleukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist.
Am Rev Respir Dis, 145 (1992), pp. 746-749
[49.]
I.K. Taylor, K.M. O'Shaughnessy, R.W. Fuller, et al.
Effect of cysteinyl-leukotriene receptor antagonist ICI 204219 on allergen-induced bronchoconstriction and airway hyperresponsiveness in atopic subjects.
Lancet, 337 (1993), pp. 690-694
[50.]
K.P. Hui, N.C. Barnes.
Lung function improvement in astma with a cysteinyl-leukotriene receptor antagonists.
Lancet, 337 (1991), pp. 1.062-1.063
[51.]
S.R. Findley, J.M. Bardem, C.B. Easley, et al.
Effects of the oral leukotriene antagonist ICI 204,219 on antigen-induced bronchoconstriction in subjects with asthma.
J Allergy Clin Immunol, 89 (1992), pp. 1.040-1.045
[52.]
K.M. O'Shaughnessy, I.K. Taylor, B. O’Connor, et al.
Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction.
Am Rev Respir Dis, 147 (1993), pp. 1.431-1.435
[53.]
S.L. Spector, L.J. Smith, M. Glass, Accolate Asthma Trialists Group.
Effects of 6-weeks of therapt with oral doses of ICI 204219, a leukotriene D4 recetor antagonist in sujbects with bronchial asthma.
Am J Respir Crit Care, 150 (1994), pp. 618-623
[54.]
B. Dahlen, D.J. Margolskee, O. Zetterström, et al.
Effect of the leukotriene receptor antagonists MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects.
Thorax, 48 (1993), pp. 1.205-1.210
[55.]
Y. Taniguchi, G. Tamura, M. Honma.
The effect of an oral leukotriene antagonists ONO-1078 on allergen-induced inmediate bronchoconstriction in asthmatic subjects.
J Allergy Clin Immunol, 92 (1993), pp. 507-512
[56.]
D.J. Margolskee, S. Bodman, R. Dockhorm, et al.
The therapeutic effect of MK-571 a potent and selective leukotriene (LT) D4 receptor antagonist in patients with chronic asthma.
J Allergy Clin Immunol, 87 (1991), pp. 677
[57.]
E. Israel, R. Dermarkarian, M. Rosemberg, et al.
The effects of a 5lypooxygenase inhibitor on asthma induced by cold dry air.
N Engl J Med, 323 (1990), pp. 1.740-1.744
[58.]
A.R. Fischer, C. McFadden, R. Frantz, et al.
Effect of chronic 5-lypooxygensase inhibition on airway hyperrresponsiveness in asthmatic subjects.
Am J Respir Crit Care Med, 152 (1995), pp. 1.203-1.207
[59.]
K.P. Hui, I.K. Taylor, G.W. Taylor.
Effect of a 5-lypooxigenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients.
Thorax, 46 (1991), pp. 184-189
[60.]
E. Israel, P. Rubin, J.P. Kemp, et al.
The effect of inhibition of 5-lypooxygenase by zileuton in mild to moderate asthma.
Ann Intern Med, 119 (1993), pp. 1.059-1.066
[61.]
K.R. Chapman, B.S. Friedman, S. Singo, et al.
The efficacy of an oral inhibitor of leukotriene synthesis (MK 0591) in asthmatics treated with inhaled steroids.
Am J Respir Crit Care Med, 149 (1994), pp. 215
[62.]
S.C. Stenton, E.N. Court, W.P. Kingston, et al.
Platelet-activating factor in bronchoalveolar lavage fluid from asthmatic subjects.
Eur Respir J, 3 (1990), pp. 408-413
[63.]
K.F. Chung, P.J. Barnes.
Effects of platelet-activating factor on airway caliber, airway responsiveness and circulating cells in asthmatic subjects.
Thorax, 44 (1989), pp. 108-115
[64.]
P. Guinot, C. Brambilla, J. Duchier, et al.
Effect of BN 52063, a specific PAF acether antagonist, on bronchial provocation test to allergens in asthmatic patients: a preliminary study.
Prostaglandins, 34 (1987), pp. 723-731
[65.]
A. Freitag, R.M. Watwon, G. Matsos, et al.
Effect of a platelet activating factor antagonist.
WEB 2086 on allergen induced asthmatic responses. Thorax, 48 (1993), pp. 594-598
[66.]
D. Spence, P.M. Johnston, P.M.A. Calverley, et al.
The effect of the orally active platelet-activating antagonists WEB 2086 in the treatment of asthma.
Am J Respir Crit Care Med, 149 (1994), pp. 1.142-1.148
[67.]
S. Hozawa, Y. Haruta, S. Ishioka, et al.
Effects of PAF antagonist Y24180 on bronchial hyperresponsiveness in patients with asthma.
Am J Respir Crit Care Med, 152 (1995), pp. 1.198-1.202
[68.]
S. Keittelman, U.J. Svendesen, P. Sjogren, et al.
The effect of a thromboxane receptor antagonist (GR32191B) in moderate to severe asthma.
Clin Exp Allergy, 20 (1990), pp. 96
[69.]
S.C. Christiansen, D. Proud, R.B. Samoff, et al.
Elevation of tissue kallikrein and kinin in the airways of asthmatic subjects after endobronchial allergen challenge.
Am Rev Respir Dis, 145 (1992), pp. 900-905
[71.]
P.G. Jorens, P.A. Vermeire, A.G. Herman.
L-arginine-dependent nitric oxide synthase: a new metabolic pathway in the lung and airways.
Eur Respir J, 6 (1993),
[72.]
S. Kharitonov, D. Yates, E. Logan-Sinlair, et al.
Endogenous nitric oxide is increased in the exaled air of asthmatic patients.
Lancet, 343 (1994), pp. 133-135
[73.]
D. Yates, S. Kharitonov, R.A. Robbins, et al.
Effect of a nitric oxyde synthase inhibitor and a glucocorticosteroid on exhaled nitric oxide.
Am J Respir Crit Care Med, 152 (1995), pp. 892-896
Copyright © 1996. Sociedad Española de Neumología y Cirugía Torácica
